Is Wells Pharmacy Network multi-month pricing actually cheaper?

Three traps recur across compounded medication programs. Titration: if a patient on a multi-month semaglutide supply moves up a dose, the remaining lower-dose product may be unusable, and the discount you booked is offset by waste. Drop-off: cash-pay patients churn, and a multi-month supply paid or stocked ahead is a loss if the patient stops before completing it. Cash flow: multi-month buys tie up working capital and inventory risk that a monthly cadence avoids. Against those risks, multi-month does offer real upside — fewer orders, lower shipping drag per dose, and simpler refill logistics — so this is a genuine trade-off, not a clear win for either option.

To evaluate it for Wells Pharmacy Network, contact Wells before committing to a cadence and ask for per-Rx estimates on both monthly and multi-month options for your highest-volume SKUs. Then compute per-dose cost under your realistic expected completion rate — not 100%. If a meaningful share of your patients will titrate or drop off before completing a multi-month supply, discount the apparent savings accordingly and compare only the adjusted per-dose figures.

Fizy Health shows resolved per-vial 503A cost on each catalog and cart line before checkout, with a separately disclosed facilitation fee at payment. Because cost is visible per vial and per strength, you can model month versus multi-month per-dose economics directly — including the waste a titration change would cause — before you commit, rather than working backward from an invoice after the order is placed.

It also supports a monthly cadence cleanly when that is the lower-risk choice. You can batch a monthly refill day in one cart, see each line's cost, and avoid stocking ahead for patients who may change dose. Compare visible per-dose cost on a monthly cadence against any Wells estimate for the same supply duration, adjusted for your real completion rate, to see which option actually wins on economics.